Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3316531 - IV
LY3316531 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is reported in the Reported Adverse Events module. An SAE is any adverse event from this study that results in 1 of the following: 1. Death 2. Initial or prolonged inpatient hospitalization 3. A life-threatening experience (that is, immediate risk of dying) 4. Persistent or significant disability/incapacity 5. Congenital anomaly/birth defect 6. Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above.
| Arm | Type | Description |
|---|---|---|
| LY3316531 (Part A) | EXPERIMENTAL | Participants received single doses of 3 milligrams (mg), 15 mg, 75 mg, 300 mg, 900 mg, or 2000 mg LY3316531 administered Intravenously (IV), or 300 mg LY3316531 administered Subcutaneously (SC). |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo matching LY3316531 administered IV. |
| LY3316531 (Part B) | EXPERIMENTAL | Participants received 3 doses of 2000 mg LY3316531 administered IV (1 dose every 4 weeks). |
| Placebo (Part B) | PLACEBO_COMPARATOR | Placebo matching LY3316531 administered IV. |
| LY3316531 (Part C) | EXPERIMENTAL | Participants with psoriasis received single doses of 300 mg LY3316531 administered IV. |
| Name | Type | Description |
|---|---|---|
| LY3316531 - IV | DRUG | Administered IV. |
| LY3316531 - SC | DRUG | Administered SC. |
| Placebo - IV | DRUG | Administered IV. |
Inclusion Criteria: * Healthy Participants * Are overtly healthy males or females, as determined by medical history and physical examination * Females must be of non-childbearing potential * Are between 18 and 64 years of age, inclusive, at screening * Have a body mass index of 18.0 to 32....
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
LY3316531 is an investigational small molecule being developed by Eli Lilly and Company for psoriasis, a chronic inflammatory skin condition. It has been studied in a Phase 1 clinical trial that enrolled healthy participants as well as participants with psoriasis. It is not yet an approved treatment.
LY3316531 is being studied for the treatment of psoriasis, a dermatologic condition. Its development is at the Phase 1 stage, so it is investigational and has not been approved for any use. The clinical work to date has involved both healthy volunteers and people with psoriasis.
LY3316531 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 study of the compound in healthy participants and participants with psoriasis.
LY3316531 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The program remains investigational, and the compound has not been approved by the FDA or any other regulatory agency for psoriasis or any other indication.
LY3316531 has been evaluated in one Phase 1 trial, NCT03418493, titled A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis. The trial was completed, enrolled 63 participants, was randomized, double blind, and placebo controlled, and was conducted in the United States.
Yes. LY3316531 - IV is an alternative name used for LY3316531, the investigational small molecule developed by Eli Lilly and Company for psoriasis. Both names refer to the same compound, which has completed a single Phase 1 trial in healthy participants and participants with psoriasis.